We’re talking about Albert Labs because they’ve announced the appointment of two scientific advisors. And the first of these is Dr. Ricardo Jorge Dinis-Oliveira. So a warm welcome to you and congratulations on your recent appointment, as the Editor-in-Chief of the “Psychoactive” journal published by the MDPI.
Now, before we get into discussing your work with Albert Labs, let’s maybe learn a bit more about you. Let’s kick this off with an introduction as to who you are and a bit about your expertise.
Thank you very much for very much for the invitation and for having me on the show I am Ricardo Dinis-Oliveira and I live in Portugal where I’m currently associate professor of the University Institute of Health Sciences and of the faculty of medicine of the University of Porto. I work regularly as a forensic expert on the effects of psychoactive substances for the Portuguese courts and media outlets, such as CNN among others.
I believe it was, my research papers, my previous research papers on psilocybin and other psychoactive substances that brought my work to the attention of Albert Labs.
Katie: All right. Well, let’s talk about that work because you’ve published over 170 peer reviewed articles on psychoactive compounds. How does your previous research that into psilocybin influence your work with Albert Labs.
In mine and many of my academic colleagues papers, there is growing evidence to support psilocybin and other psychoactive drugs having a positive effects on the brain function and mental health.
It was actually my previous publications, my previous data, that supports the benefits of these drugs that brought the attention of Albert Labs. Particularly psilocybin has the potential to safely heal people if the correct doses are used. It will be my duty in this collaboration with Albert Labs and as a toxicologist in the clinical and forensic areas to ensure patient’s safety in the administration of psilocybin during the Albert Labs clinical studies and trials.
All right. So you’ll be working directly with Albert Labs on their natural psilocybin medicine, which is KRN-101, maybe tell us a bit more about your role within Albert Labs then.
Well, there is the exciting potential for helping people at scale through innovative cultivation, patents, and licensing & regulation expertise.
My team and I will ensure that all Albert Labs’ important work will be complete from the toxicology and pharmacology point of view. Our objective is to ensure the quality and the safety profile of their drugs.
I’m looking forward to being a part of the future of this company that will be safely and effectively administering psilocybin as a compliment to other pharmacological treatments, chemical treatment, but also I believe that this drug psilocybin could complement psychotherapy for people with the urgent and unmet needs, especially for that not being well-treated and are refractory to conventional treatments.
Dr. Ricardo, thank you very much, indeed for sharing your expertise with us here at Proactive London.
Read the full press release here.
The original was posted via Proactive London here.
© 2023 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact [email protected]